Special Episode: Is Herd Immunity Even Possible?
Amid declining rates of vaccinations in the U.S, virus mutations and a crisis in India, is herd immunity from COVID-19 still achievable? The latest insights from Biotech equity analyst, Matthew Harrison.
6 Touko 202111min
Michael Zezas: Texas vs. California
The Supreme Court is expected to deliver a decision soon on this key case for the future of the Affordable Care Act and the 20 million Americans who have acquired coverage under it. The outcome could have significant impacts for investor too.
5 Touko 20212min
Vishy Tirupattur: Is the U.S. in a Housing Bubble?
The red-hot U.S. housing market brings to mind some unhappy memories of the 2006 bubble, but there are some key differences this time around.
4 Touko 20214min
Adam Virgadamo: For Stocks, Reopening Is All About Nuance
The reality of reopening is anything but cut and dry. And how the market is pricing, or failing to price, nuances should continue to be a key theme.
3 Touko 20213min
Chetan Ahya: Could Centrals Banks Shake Up Digital Currencies?
Plans to introduce digital currencies are gaining momentum among the world’s central banks. But what level of disruption will it bring to the financial system?
30 Huhti 20214min
Michael Zezas: On Infrastructure, Follow the Money
Last night, President Biden laid out his vision to rebuild the existing U.S. infrastructure. Here are three takeaways and sectors to watch as negotiations unfold.
29 Huhti 20212min
Andrew Sheets: A Choppier, More Range-bound Summer?
Summer months have historically seen lower, more volatile returns, but strong year-to-date gains and potentially higher inflation could intensify that trend.
28 Huhti 20213min
Graham Secker: 4 Reasons to Consider European Equities
Europe's 'unloved' quality among global investors is not the only reason to feel optimistic about the potential for outperformance among European equities. Chief European Equity Analyst Graham Secker explains.
27 Huhti 20213min
